$128.18
0.38% day before yesterday
NYSE, Nov 28, 09:30 pm CET
ISIN
US98978V1035
Symbol
ZTS

Zoetis, Inc. Class A Stock price

$128.18
-17.23 11.85% 1M
-37.22 22.50% 6M
-34.75 21.33% YTD
-48.56 27.48% 1Y
-19.95 13.47% 3Y
-32.20 20.08% 5Y
+81.48 174.48% 10Y
+97.17 313.35% 20Y
NYSE, Closing price Fri, Nov 28 2025
+0.49 0.38%

New AI Insights on Zoetis, Inc. Class A Insights AI Insights on Zoetis, Inc. Class A

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$53.8b
Enterprise Value
$58.8b
Net debt
$5.0b
Cash
$2.1b
Shares outstanding
441.5m
Valuation (TTM | estimate)
P/E
21.4 | 20.0
P/S
5.7 | 5.6
EV/Sales
6.3 | 6.1
EV/FCF
26.2
P/B
10.0
Dividends
DPS
$1.80
Yield 1Y | 5Y
1.4% | 0.8%
Growth 1Y | 5Y
15.4% | 21.0%
Payout 1Y | 3Y
32.8% | 31.3%
Increased
12 Years
Financials (TTM | estimate)
Revenue
$9.4b | $9.6b
EBITDA
$3.7b | $4.2b
EBIT
$3.6b | $3.7b
Net Income
$2.7b | $2.8b
Free Cash Flow
$2.2b
Growth (TTM | estimate)
Revenue
2.7% | 3.8%
EBITDA
7.0% | 18.5%
EBIT
7.7% | 10.2%
Net Income
9.1% | 13.9%
Free Cash Flow
-3.0%
Margin (TTM | estimate)
Gross
71.7%
EBITDA
39.6% | 43.6%
EBIT
38.3%
Net
28.2% | 29.5%
Free Cash Flow
23.8%
Financial Health
Equity Ratio
33.5%
Return on Equity
52.1%
ROCE
26.9%
ROIC
23.0%
Debt/Equity
1.3
More
EPS
$6.0
FCF per Share
$5.1
Short interest
1.9%
Employees
14k
Rev per Employee
$670.0k
Show more

Is Zoetis, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Zoetis, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Zoetis, Inc. Class A forecast:

17x Buy
71%
7x Hold
29%

Analyst Opinions

24 Analysts have issued a Zoetis, Inc. Class A forecast:

Buy
71%
Hold
29%

Financial data from Zoetis, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
9,397 9,397
3% 3%
100%
- Direct Costs 2,658 2,658
3% 3%
28%
6,739 6,739
5% 5%
72%
- Selling and Administrative Expenses 2,368 2,368
5% 5%
25%
- Research and Development Expense 685 685
2% 2%
7%
3,725 3,725
7% 7%
40%
- Depreciation and Amortization 131 131
9% 9%
1%
EBIT (Operating Income) EBIT 3,594 3,594
8% 8%
38%
Net Profit 2,651 2,651
9% 9%
28%

In millions USD.

Don't miss a Thing! We will send you all news about Zoetis, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zoetis, Inc. Class A Stock News

Neutral
Business Wire
2 days ago
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Lenivia is a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties ...
Neutral
Business Wire
9 days ago
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. Kristin Peck, Chief Executive Officer and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. Investors and othe...
Neutral
Business Wire
10 days ago
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025, featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Executive Vice President and Chief Financial Officer; Rob Polzer, Ph.D., Executive Vice President and President of Research and Development; and Kevin Esch, D.V.M, M.P.H., P...
More Zoetis, Inc. Class A News

Company Profile

Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. The company operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The company provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals. Zoetis was founded in 1952 and is headquartered in Parsippany, NJ.

Head office United States
CEO Kristin Peck
Employees 13,800
Founded 1952
Website www.zoetis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today